Medicine, Hematology Oncology Division

Grants

Grants per year 1995 2007 2008 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2028

• 479 Active
• 1103 Finished

Grants per year

Search results

• Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial

  Hitsman, B. L., Kalhan, R., Mohindra, N. A., Patel, J. D. & Spring, B.

  University of Pennsylvania, National Cancer Institute

  6/1/16 → 5/31/18

  Project: Research project

• Prot #145515: NU UCSF15U05: A Phase 1b/2 Study of the Oral CDK4/6 Inhibitor LEE011 (Ribociclib) in Combination with Docetaxel plus Prednisone in Metastatic Castration Resistant Prostate Cancer

  Carneiro Filho, B. A. & Hussain, M.

  Prostate Cancer Clinical Trials Consortium, LLC, Novartis Pharmaceuticals Corporation

  5/25/16 → 12/31/18

  Project: Research project

• Prot #VX12-970-001: An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors

  Gradishar, W. J.

  Quintiles, Inc., Vertex Pharmaceuticals Incorporated

  5/16/16 → 5/16/19

  Project: Research project

• Prot #NU UM16U03: A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer.

  Carneiro Filho, B. A.

  University of Michigan, Pfizer Inc.

  5/16/16 → 12/31/17

  Project: Research project

• Prot #IMDZ-C232: A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients with Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1

  Agulnik, M.

  Immune Design Corp.

  5/12/16 → 5/12/21

  Project: Research project

• Prot #COTI2-101: A Phase 1 Study Of COTI-2 For The Treatment Of Advanced Or Recurrent Gynecologic Malignancies

  Matei, D. E. & Chae, Y. K.

  Critical Outcome Technologies Inc.

  5/2/16 → 5/2/19

  Project: Research project

• Melanoma Research Professor in Translational Medicine

  Sosman, J. A.

  American Cancer Society

  5/1/16 → 12/31/19

  Project: Research project

  • Melanoma 100%
  • Translational Medical Research 94%
  • Neoplasms 47%
  • Mutation 20%
  • Neoplasm Genes 20%

• Mechanisms of Leukemogenesis in Down Syndrome

  Crispino, J. D.

  National Cancer Institute

  5/1/16 → 4/30/17

  Project: Research project

• Aberrant Megakaryopoiesis in the Myeloproliferative Neoplasms

  Crispino, J. D.

  National Heart, Lung, and Blood Institute

  5/1/16 → 4/30/17

  Project: Research project

• Prot #D4190C00023: A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination with Tremelimumab or AZD9150 in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma

  Pro, B.

  ICON Clinical Research, LLC, MedImmune, LLC

  4/29/16 → 4/29/19

  Project: Research project

• Prot #INCB 59872-101: A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies

  Chae, Y. K.

  inVentiv Health Clinical, Incyte Corporation

  4/14/16 → 4/14/22

  Project: Research project

• Prot #201501057: NU WU15S01: A Phase II Study of Pazopanib as Front-Line Therapy in Patients with Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy

  Agulnik, M.

  Washington University St. Louis, GlaxoSmithKline LLC

  4/12/16 → 4/12/22

  Project: Research project

• IPA Agreement for Condello, Salvatore

  Matei, D. E.

  Jesse Brown VA Medical Center

  4/1/16 → 9/30/16

  Project: Research project

• The Role of NOV (CCN3) in Prostate Cancer Progression

  Yu, J.

  National Cancer Institute

  4/1/16 → 3/31/19

  Project: Research project

• Prot #D791PC00001: A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of gefitinib in Combination with MEDI4736 (anti PD-L1) in Subjects with Non-Small Cell Lung Cancer(NSCLC)

  Chae, Y. K.

  DrugDev Inc., AstraZeneca Pharmaceuticals LP

  3/31/16 → 3/31/19

  Project: Research project

• An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer

  Matei, D. E.

  National Cancer Institute

  3/28/16 → 1/31/20

  Project: Research project

  • guadecitabine 100%
  • Epigenome 93%
  • Ovarian Neoplasms 73%
  • Platinum 65%
  • Carboplatin 58%

• Prot #391402: A Phase 1/2a, Open-Label, Parallel, Two-Arm Dose-Escalation Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BAX69 in Subjects with Refractory Ovarian Cancer with Malignant Ascites

  Chae, Y. K.

  Quintiles, Inc., Baxalta US Inc.

  3/17/16 → 3/17/19

  Project: Research project

• Prot #FLX925-01: Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects with Relapsed or Refractory Acute Myeloid Leukemia

  Dinner, S. N.

  Medpace, Inc., FLX Bio, Inc.

  3/16/16 → 3/16/19

  Project: Research project

• Prot #265-109: Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

  Mohindra, N. A.

  Clinverse, Inc., Mirati Therapeutics Inc.

  3/14/16 → 3/14/19

  Project: Research project

• Prot #M15-330: A Phase 1b/2 Study of Duvelisib and Venetoclax in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3

  Ma, S.

  AbbVie Inc.

  3/3/16 → 3/3/19

  Project: Research project

• The role of ICSBP in the pathogenesis of chronic myeloid leukemia

  Eklund, E. A. & Huang, W.

  National Cancer Institute

  3/1/16 → 2/28/19

  Project: Research project

• Targeting CCR5 in Cancer Treatment

  Cristofanilli, M.

  Thomas Jefferson University, Dr. Ralph and Marian Falk Medical Research Trust

  2/29/16 → 12/31/16

  Project: Research project

  • Staining and Labeling 100%
  • Safety 90%
  • Preliminary Data 83%
  • Research Ethics Committees 81%
  • Clinical Trials 50%

• Prot #HM-EMSI-202: A Single-Arm, Open-Label, Phase 2 Study Evaluating The Efficacy, Safety And Pharmacokinetics Of HM61713 In Patients With T790M-Positive Non-Small Cell Lung Cancer (NSCLC) After Treatment With An Epidermal Growth Factor Receptor-Tyrosine

  Chae, Y. K.

  Parexel, Hanmi Pharmaceutical Co., Ltd.

  1/26/16 → 1/26/19

  Project: Research project

• Prot #015001: The ROCKET Study: A Phase 2, Single-arm, Multicenter Trial to Determine the Efficacy and Safety of JCAR015 in Adult Subjects with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

  Dinner, S. N.

  Juno Therapeutics, Inc.

  1/8/16 → 1/8/19

  Project: Research project

• A Single Arm Phase II Study Evaluating the Efficacy and Safety of MEDI4736 in Combination with Tremelimumab in Patients with Metastatic HER2 Negative Breast Cancer

  Cristofanilli, M., Santa-Maria, C. A. & Blanco Jr, L. Z.

  Avon Products Foundation, Inc.

  1/1/16 → 12/31/18

  Project: Research project

  • tremelimumab 100%
  • durvalumab 96%
  • Breast Neoplasms 53%
  • Progression-Free Survival 50%
  • Safety 40%